Dosage Forms – Talk Bio

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Bay Area, biotech industry, Dosage Forms, genentech, layoffs, Roche (company), South San Francisco, WARN filing

Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001

4 months ago talkbio0Tagged Alumis, Dermatology field, Dosage Forms, ESK-001, Inhibitor, Japan, Kaken, licensing agreement, TYK2 gene

Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan

Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal

4 months ago talkbio0Tagged Dosage Forms, licensing agreement, Polycythemia, RNA-targeted medicine, Sapablursen, vera

Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine

Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront

4 months ago talkbio0Tagged chronic, Dosage Forms, KRP, KRP-M223, Kyorin, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, chronic spontaneous urticaria, licensing deal, MRGPRX2 antagonist

Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases

4 months ago talkbio0Tagged Antagonist muscle action, chronic, Dosage Forms, Dupixent, KRP, KRP-M223, Kyorin, licensing agreement, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

5 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

FDA Approves Ono Pharmaceutical’s Romvimza for Rare Joint Tumor

5 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, Deciphera acquisition, Dosage Forms, Fibrous histiocytoma of tendon sheath, Infrequent, Romvimza, tenosynovial, United States Food and Drug Administration

Romvimza, tenosynovial giant cell tumor (TGCT), FDA approval, Ono Pharmaceutical, Deciphera acquisition, kinase inhibitor, rare cancer treatment